Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer

Approximately 12–15% of gastric cancers (GCs) are human epidermal growth factor receptor-2 (HER2)-positive (HER2 immunohistochemistry 3 + or 2 + /in situ hybridization + [ERBB2/CEP17 ≥ 2.0]). While the anti-HER2 monoclonal antibody trastuzumab, in combination with chemotherapy, is the standard treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shitara, Kohei, Baba, Eishi, Fujitani, Kazumasa, Oki, Eiji, Fujii, Satoshi, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205906/
https://www.ncbi.nlm.nih.gov/pubmed/33997928
http://dx.doi.org/10.1007/s10120-021-01196-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205906/
https://www.ncbi.nlm.nih.gov/pubmed/33997928
http://dx.doi.org/10.1007/s10120-021-01196-3

Ejemplares similares